MD4763B1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
MD4763B1
MD4763B1 MDA20180049A MD20180049A MD4763B1 MD 4763 B1 MD4763 B1 MD 4763B1 MD A20180049 A MDA20180049 A MD A20180049A MD 20180049 A MD20180049 A MD 20180049A MD 4763 B1 MD4763 B1 MD 4763B1
Authority
MD
Moldova
Prior art keywords
pharmaceutical composition
levocarnitine
consequences
injections
medicine
Prior art date
Application number
MDA20180049A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD20180049A2 (en
MD4763C1 (en
Inventor
Микола Иванович ГУМЕНЮК
Original Assignee
M. T. K. Medical Center Limited Liability Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from UAU201511330U external-priority patent/UA106905U/en
Priority claimed from UAA201611435A external-priority patent/UA119768C2/en
Application filed by M. T. K. Medical Center Limited Liability Company filed Critical M. T. K. Medical Center Limited Liability Company
Publication of MD20180049A2 publication Critical patent/MD20180049A2/en
Publication of MD4763B1 publication Critical patent/MD4763B1/en
Publication of MD4763C1 publication Critical patent/MD4763C1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to medicine, namely to means for the treatment of ischemic heart disease and its consequences. The pharmaceutical composition contains arginine hydrochloride, levocarnitine and water for injections.
MDA20180049A 2015-11-17 2016-11-16 Pharmaceutical composition MD4763C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
UAU201511330U UA106905U (en) 2015-11-17 2015-11-17 Pharmaceutical formulation
UAA201611435A UA119768C2 (en) 2016-11-11 2016-11-11 PHARMACEUTICAL COMPOSITION
PCT/IB2016/056901 WO2017085642A1 (en) 2015-11-17 2016-11-16 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
MD20180049A2 MD20180049A2 (en) 2018-09-30
MD4763B1 true MD4763B1 (en) 2021-08-31
MD4763C1 MD4763C1 (en) 2022-03-31

Family

ID=58718454

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20180049A MD4763C1 (en) 2015-11-17 2016-11-16 Pharmaceutical composition

Country Status (2)

Country Link
MD (1) MD4763C1 (en)
WO (1) WO2017085642A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022018705A1 (en) * 2020-07-24 2022-01-27 M.T.K. Medical Center Limited Liability Company A pharmaceutical composition for treating cardiovascular and cerebrovascular disorders,diseases in pregnant women and improving exercise tolerance
UA126094C2 (en) * 2020-07-24 2022-08-10 Тов "Медичний Центр "М.Т.К." Use of an infusion solution for treating diseases related to cerebral circulation disorders
WO2022018707A1 (en) * 2020-07-24 2022-01-27 M.T.K. Medical Center Limited Liability Company Infusion solution comprising arginine hydrochloride and levocarnitine for treatment and prevention of diseases in pregnant women and promotion of fetal development during pregnancy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101336914B (en) * 2007-07-03 2011-12-28 常州高新技术产业开发区三维工业技术研究所有限公司 Medicine combination capable of reducing myocardial infarction area and use thereof
CN103948581B (en) * 2014-02-26 2018-05-08 青岛大学医学院附属医院 Levocarnitine combines L-arginine and is preparing the application in treating diabetic retinopathy neurotrosis medicine

Also Published As

Publication number Publication date
WO2017085642A1 (en) 2017-05-26
MD20180049A2 (en) 2018-09-30
MD4763C1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
JOP20210109A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018500569A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017500571A1 (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017501272A1 (en) Indole derivatives as dengue viral replication inhibitors
EA201691481A1 (en) C5a inhibitors for the treatment of viral pneumonia
JOP20160198B1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
MD4763C1 (en) Pharmaceutical composition
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA201691796A1 (en) N-SUBSTITUTED ASYMMETRIC UREA AND THEIR APPLICATION IN MEDICINE
MX2017006747A (en) Fatty acid amides for the prevention and/or treatment of steatohepatitis.
TR201903234T4 (en) Pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease.
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
UA106905U (en) Pharmaceutical formulation
MD20150017A2 (en) Use of Polybiolin drug in patients with liver cirrhosis
LV15072A (en) Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inos gene
BR112017003900A2 (en) testosterone formulations and treatment methods with them

Legal Events

Date Code Title Description
FG4A Patent for invention issued